Cargando…
Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients
AIMS: Hereditary haemochromatosis is a genetic disorder that is caused by several known mutations in the human homeostatic iron regulator protein (HFE) gene. Abnormal accumulation of iron causes a joint disease that resembles osteoarthritis (OA), but appears at a relatively younger age and is accomp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Editorial Society of Bone & Joint Surgery
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711657/ https://www.ncbi.nlm.nih.gov/pubmed/34905938 http://dx.doi.org/10.1302/2633-1462.212.BJO-2021-0162.R1 |
_version_ | 1784623408187703296 |
---|---|
author | Krasin, Elisha Gold, Aviram Morgan, Samuel Warschawski, Yaniv |
author_facet | Krasin, Elisha Gold, Aviram Morgan, Samuel Warschawski, Yaniv |
author_sort | Krasin, Elisha |
collection | PubMed |
description | AIMS: Hereditary haemochromatosis is a genetic disorder that is caused by several known mutations in the human homeostatic iron regulator protein (HFE) gene. Abnormal accumulation of iron causes a joint disease that resembles osteoarthritis (OA), but appears at a relatively younger age and is accompanied by cirrhosis, diabetes, and injury to other organs. Increased serum transferrin saturation and ferritin levels are known markers of haemochromatosis with high positive predictive values. METHODS: We have retrospectively analyzed the iron studies of a cohort of 2,035 patients undergoing knee joint arthroplasty due to OA. RESULTS: No patients had HFE gene C282Y, S65C, or H63D mutations testing. In total, 18 patients (2.96%) of the male cohort and 51 (3.58%) of the female cohort had pathologically increased ferritin levels that may be indicative of haemochromatosis. Seven patients (0.34%) had serum transferrin saturation above 45%. CONCLUSION: The awareness for the diagnosis of this disorder in Orthopaedics is low and needs improvement. Osteoarthritic patients undergoing knee arthroplasty should be routinely screened for haemochromatosis by iron studies and referred to genetic testing when needed. Level of evidence: Level III - Retrospective cohort study. Cite this article: Bone Jt Open 2021;2(12):1062–1066. |
format | Online Article Text |
id | pubmed-8711657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The British Editorial Society of Bone & Joint Surgery |
record_format | MEDLINE/PubMed |
spelling | pubmed-87116572022-01-13 Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients Krasin, Elisha Gold, Aviram Morgan, Samuel Warschawski, Yaniv Bone Jt Open Knee AIMS: Hereditary haemochromatosis is a genetic disorder that is caused by several known mutations in the human homeostatic iron regulator protein (HFE) gene. Abnormal accumulation of iron causes a joint disease that resembles osteoarthritis (OA), but appears at a relatively younger age and is accompanied by cirrhosis, diabetes, and injury to other organs. Increased serum transferrin saturation and ferritin levels are known markers of haemochromatosis with high positive predictive values. METHODS: We have retrospectively analyzed the iron studies of a cohort of 2,035 patients undergoing knee joint arthroplasty due to OA. RESULTS: No patients had HFE gene C282Y, S65C, or H63D mutations testing. In total, 18 patients (2.96%) of the male cohort and 51 (3.58%) of the female cohort had pathologically increased ferritin levels that may be indicative of haemochromatosis. Seven patients (0.34%) had serum transferrin saturation above 45%. CONCLUSION: The awareness for the diagnosis of this disorder in Orthopaedics is low and needs improvement. Osteoarthritic patients undergoing knee arthroplasty should be routinely screened for haemochromatosis by iron studies and referred to genetic testing when needed. Level of evidence: Level III - Retrospective cohort study. Cite this article: Bone Jt Open 2021;2(12):1062–1066. The British Editorial Society of Bone & Joint Surgery 2021-12-15 /pmc/articles/PMC8711657/ /pubmed/34905938 http://dx.doi.org/10.1302/2633-1462.212.BJO-2021-0162.R1 Text en © 2021 Author(s) et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND 4.0) licence, which permits the copying and redistribution of the work only, and provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | Knee Krasin, Elisha Gold, Aviram Morgan, Samuel Warschawski, Yaniv Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients |
title | Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients |
title_full | Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients |
title_fullStr | Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients |
title_full_unstemmed | Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients |
title_short | Screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients |
title_sort | screening for hereditary haemochromatosis in patients undergoing knee arthroplasty: a retrospective cohort study of 2,035 patients |
topic | Knee |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8711657/ https://www.ncbi.nlm.nih.gov/pubmed/34905938 http://dx.doi.org/10.1302/2633-1462.212.BJO-2021-0162.R1 |
work_keys_str_mv | AT krasinelisha screeningforhereditaryhaemochromatosisinpatientsundergoingkneearthroplastyaretrospectivecohortstudyof2035patients AT goldaviram screeningforhereditaryhaemochromatosisinpatientsundergoingkneearthroplastyaretrospectivecohortstudyof2035patients AT morgansamuel screeningforhereditaryhaemochromatosisinpatientsundergoingkneearthroplastyaretrospectivecohortstudyof2035patients AT warschawskiyaniv screeningforhereditaryhaemochromatosisinpatientsundergoingkneearthroplastyaretrospectivecohortstudyof2035patients |